Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company. The partnership aims to develop and commercialize innovative RNA-editing therapies utilizing Rznomics' proprietary trans-splicing ribozyme platform.

The collaboration is centered on the discovery and development of RNA-editing therapeutics targeting sensorineural hearing loss. Under the terms of the agreement, Rznomics will lead early-stage research based on jointly approved plans, while Eli Lilly will take over subsequent development and commercialization efforts.

Should Lilly choose to exercise all available options under the agreement, the total deal value could exceed $1.3 billion, in addition to tiered royalties on future product sales. The upfront payment details remain undisclosed in accordance with the mutual agreement between both parties.

Dr. Seong-Wook Lee, CEO of Rznomics, described the partnership as a major validation of the company’s RNA-editing platform, emphasizing its potential to address previously untreatable conditions. He expressed confidence in the collaboration’s capacity to accelerate the development of transformative therapies on a global scale.

This agreement represents a pivotal moment for Rznomics in expanding its international footprint within the biotech sector. For Eli Lilly, the collaboration supports its strategic commitment to building a robust RNA therapeutics pipeline and tackling significant unmet medical needs, particularly in the area of hearing loss.

Source: https://www.rznomics.com/bbs/?so_table=promote_en&mode=VIEW&num=114&category=&findType=&findWord=&sort1=&sort2=&page=1